Paget-Advance
Financiado
Advancing knowledge to improve outcome in Paget s disease of bone
Paget’s disease of bone (PDB) is a common skeletal disorder in people of European descent characterised by abnormal bone remodeling which disrupts normal bone structure causing pain, deformity, nerve compression syndromes and frac...
Paget’s disease of bone (PDB) is a common skeletal disorder in people of European descent characterised by abnormal bone remodeling which disrupts normal bone structure causing pain, deformity, nerve compression syndromes and fractures.
The causes of PDB are incompletely understood. Genetic factors play a key role and some predisposing genes been identified but many remain to be discovered as do the mechanisms by which these genes influence bone cell function. Environmental factors also contribute but these are poorly defined, and it remains unclear how genes and environment interact to regulate susceptibility and severity. Further research is required to permit earlier diagnosis and to define the genetic and environmental factors that influence susceptibility to PDB so that new therapeutic strategies can be developed to improve outcome.
The Paget-Advance programme will progress beyond state-of-the-art by identifying new genetic variants that predispose to PDB by extended genome wide association studies and next generation sequencing of early onset familial cases where the causal genes are unknown. A genetic profiling test will be developed to facilitate early diagnosis and treatment. The functional mechanisms by which the variants affect bone cell function will be investigated using bioinformatics, cell culture studies and preclinical disease models. Potential environmental triggers will be explored focusing on the intestinal microbiome diet and biomechanical loading using preclinical disease models and prospective clinical studies.
The result will be to increase understanding of PDB and to facilitate earlier diagnosis and timely therapeutic intervention which will improve clinical outcome for patients and those at risk of the disease. The research will also have wider significance in advancing knowledge of the fundamental processes that regulate bone remodelling with potential spinoffs for other bone diseases.
ver más
Duración del proyecto: 85 meses
Fecha Inicio: 2018-06-19
Fecha Fin: 2025-07-31
Fecha Fin: 2025-07-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-06-19
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2017-ADG:
ERC Advanced Grant
Cerrada
hace 7 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
THE UNIVERSITY OF EDINBURGH
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
301.83K€ |
Participante